LVIP02-LC2-2-BE1, SP-Epi-RPE65-BE1, Clone 10.1
The cell line is not validated yet.
LVPEIi005-A-1
General
iPSC Line |
|
| hPSCreg name | LVPEIi005-A-1 |
| Cite as: | LVPEIi005-A-1 (RRID:CVCL_E4X9) |
| Alternative name(s) |
LVIP02-LC2-2-BE1, SP-Epi-RPE65-BE1, Clone 10.1
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 7th September 2026 |
| Notes | This patient specific induced pluripotent stem cell (iPSC) line is a sub-clone of the parental LCA2 patient-specific iPSC line (LVPEIi005-A), that has been gene edited to correct the pathogenic mutation, using the en31-FnCas9-ABE construct. The parental iPSC line carried a homozygous missense mutation in exon 9 of RPE65 (c.992G>A; p.Trp331Ter), which was then base edited and corrected as RPE65 (c.992A>G; p.Ter331Trp). This mutation corrected iPSC line has been stably expanded post-editing and genotyping and were characterized after passage 10. The line maintains a normal karyotype and expresses the stem cell markers OCT4, SOX2, NANOG, KLF4 and SSEA4. It also efficiently differentiates into all three germ cell lineages and formed retinal organoids and mature retinal pigmented epithelial (RPE) cells. The full length RPE65 protein expression is fully restored to normal levels in these mature iPSC-RPE cells. |
| User feedback | |
Provider |
|
| Generator | L.V. Prasad Eye Institute (LVPEI) |
| Owner | L.V. Prasad Eye Institute (LVPEI) |
| Distributors | |
| Derivation country | India |
External iPSC Databases |
|
| Cellosaurus | CVCL_E4X9 |
| BioSamples | SAMEA117748715 |
General iPSC Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Additional restrictions:
Terms and conditions applied for commercial use |
| Subclone of | |
iPSC Genetic Modification
| Disease/phenotype related modifications |
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Asian (Indian), 24 years |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | Yes |
| Is clinical information available? | Clinical information will be provided on request |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA115169989 |
Ethics
Also have a look at the ethics information for the parental line
LVPEIi005-A
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | The gene editing vector plasmid, en31FnCas9-ABEmax8.17d, was obtained from the collaborator Dr. Debojyoti Chakraborty's lab at CSIR-IGIB. The RPE65 targeting CRISPR guide oligo was then cloned into the BbsI site, downstream of the U6 promoter. |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | For research use only |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
LVPEIi005-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | The vector backbone specific regions were found to be lost by passage 5 |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Clonies were seeded at low density and manually picked for clonal expansion |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
||||
| KLF4 |
Yes |
|
||||
| hTERT |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Protocol or reference
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.